Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE Healthcare鈥檚 latest 10-K tops 300 pages and is packed with details on MRI backlogs, contrast-agent regulations, and high-margin service contracts鈥攊nformation critical yet time-consuming to dissect. If you have ever searched for 鈥淕E Healthcare insider trading Form 4 transactions鈥� or wondered where the quarterly segment data hides, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries translate dense disclosures into plain language, flagging the numbers that matter and linking them to the exact page in the filing. Whether you need the 鈥淕E Healthcare quarterly earnings report 10-Q filing鈥� five minutes after it hits EDGAR or an alert on a sudden 鈥淕E Healthcare 8-K material events explained,鈥� you receive real-time updates plus expert context鈥攏o manual page flipping required.
Use our platform to:
- Track 鈥淕E Healthcare executive stock transactions Form 4鈥� in real time and spot buying or selling trends.
- Compare R&D spend across Imaging, Ultrasound, and Pharmaceutical Diagnostics without combing through footnotes.
- Understand the 鈥淕E Healthcare annual report 10-K simplified鈥� with AI-generated overviews, ratios, and red-flag alerts.
- Review the 鈥淕E Healthcare proxy statement executive compensation鈥� to see how leadership pay aligns with performance.
- Download every exhibit, amendment, and 鈥淕E Healthcare Form 4 insider transactions real-time鈥� feed in one place.
From cash-flow trends to device-approval milestones, our comprehensive coverage of all filing types鈥�10-K, 10-Q, 8-K, Form 4, S-8, and more鈥攇ives you the clarity needed to make informed decisions. Understanding GE Healthcare SEC documents with AI has never been this straightforward.
GE HealthCare (GEHC) posted another solid quarter. Q2-25 revenue rose 3% YoY to $5.01 bn, driven by an outsized 14% jump in Pharmaceutical Diagnostics (PDx) that offset low-single-digit growth in Imaging (+2%), Advanced Visualization Solutions (+3%) and Patient Care Solutions (+1%). Operating income climbed 8% to $654 m and the operating margin expanded 50 bps to 13.1% on tighter SG&A and R&D spend. Net income attributable to GEHC advanced 14% to $486 m, lifting diluted EPS to $1.06 (vs $0.93).
For the first half, revenue increased 3% to $9.78 bn while diluted EPS surged 31% to $2.29, aided by a $97 m revaluation gain on the Nihon Medi-Physics step-up acquisition. Cash from operations improved 15% to $344 m; period-end cash reached $3.8 bn after issuing $1.5 bn of new 4.8%-5.5% notes and repurchasing $100 m of shares. Net debt rose to ~$6.5 bn, but leverage remains near 2脳 EBITDA.
Balance-sheet strength, higher service backlog (RPO $15.3 bn, +6% YTD) and segment EBIT growth in AVS and PDx support FY-25 guidance. Headwinds include lower Imaging/PCS EBIT, a slight dip in gross profit (-0.8 % YoY) and higher inventory. Management continues to target productivity gains, incremental pricing and integration of recent software and radiopharma acquisitions.
Clarivate Plc (NYSE: CLVT) filed an 8-K disclosing several leadership changes. President, Intellectual Property Gordon Samson will step down on 7 Sep 2025 and remain in a non-executive capacity until 31 Dec 2025. Under a compromise agreement signed 25 Jul 2025, Samson will receive a lump-sum cash payment of 拢1,458,552, accelerated vesting of RSUs scheduled to vest within 18 months, and, if needed, a UK tax equalisation payment, contingent on standard release and restrictive-covenant obligations.
Board director Valeria Alberola has notified the company she will resign effective 31 Dec 2025, citing a change in primary employment and confirming no disagreement with management or the Board.
To ensure continuity, Clarivate announced that Maroun S. Mourad will assume the role of President, Intellectual Property on 8 Sep 2025. The related press release is furnished as Exhibit 99.1. The filing contains no financial results or forward-looking guidance.
United Therapeutics Corp. (UTHR) 鈥� Form 144 filing. Director-level insider Paul Mahon has filed to sell an additional 11,000 common shares on or about 24 Jul 2025 through Morgan Stanley Smith Barney. At the indicated market value of $3.35 million, the block equals roughly 0.024 % of the 45.1 million shares outstanding.
The filing also discloses recent insider dispositions totaling 66,000 shares over the past three months, generating $19.56 million in gross proceeds. Including the planned sale, Mahon鈥檚 cumulative dispositions would reach 77,000 shares, or ~0.17 % of shares outstanding. All shares derive from stock-option exercises paid in cash.
No company financials are provided; the document is strictly a notice required by Rule 144. While the absolute share count is modest, continued insider selling may attract investor attention. The filing confirms regulatory compliance and does not assert possession of undisclosed adverse information.
FAQ
What is the current stock price of Ge Healthcare Technologies (GEHC)?
What is the market cap of Ge Healthcare Technologies (GEHC)?
What are the core business segments of GE Healthcare Technologies Inc?
How does GE Healthcare generate recurring revenue?
What makes GE Healthcare's products unique in the medical technology market?
How does GE Healthcare address the challenges of operating in a regulated industry?
What role does advanced visualization play in GE Healthcare's offerings?
How does GE Healthcare support global healthcare providers?
How does GE Healthcare maintain operational excellence through service offerings?
What distinguishes GE Healthcare in the competitive landscape of medical technology?
